Moreover, EHP-101 could reduce expression of key SSc biomarker genes e.g., C-C motif chemokine 2 (CCL2) or the interleukin 13 receptor subunit alpha 1 (IL-13Rα1). The gene discussed is CCL2; the disease is systemic sclerosis.